EGFR-targeted therapeutics delivered as monotherapies for treatment of SCCHN have demonstrated fewer toxicities compared to combined modality treatment regimens but only marginal clinical response (4–10%) [7, 8]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.